JP2009536036A5 - - Google Patents

Download PDF

Info

Publication number
JP2009536036A5
JP2009536036A5 JP2009510114A JP2009510114A JP2009536036A5 JP 2009536036 A5 JP2009536036 A5 JP 2009536036A5 JP 2009510114 A JP2009510114 A JP 2009510114A JP 2009510114 A JP2009510114 A JP 2009510114A JP 2009536036 A5 JP2009536036 A5 JP 2009536036A5
Authority
JP
Japan
Prior art keywords
cells
epitope
autoreactive
acid sequence
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009510114A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009536036A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/068304 external-priority patent/WO2007131210A2/en
Publication of JP2009536036A publication Critical patent/JP2009536036A/ja
Publication of JP2009536036A5 publication Critical patent/JP2009536036A5/ja
Withdrawn legal-status Critical Current

Links

JP2009510114A 2006-05-05 2007-05-04 Ｔ細胞ワクチン Withdrawn JP2009536036A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74661106P 2006-05-05 2006-05-05
US74790306P 2006-05-22 2006-05-22
PCT/US2007/068304 WO2007131210A2 (en) 2006-05-05 2007-05-04 T-cell vaccine

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2013163134A Division JP6000205B2 (ja) 2006-05-05 2013-08-06 Ｔ細胞ワクチン
JP2016003678A Division JP2016053090A (ja) 2006-05-05 2016-01-12 Ｔ細胞ワクチン

Publications (2)

Publication Number Publication Date
JP2009536036A JP2009536036A (ja) 2009-10-08
JP2009536036A5 true JP2009536036A5 (enExample) 2013-09-19

Family

ID=38668612

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2009510114A Withdrawn JP2009536036A (ja) 2006-05-05 2007-05-04 Ｔ細胞ワクチン
JP2013163134A Expired - Fee Related JP6000205B2 (ja) 2006-05-05 2013-08-06 Ｔ細胞ワクチン
JP2016003678A Withdrawn JP2016053090A (ja) 2006-05-05 2016-01-12 Ｔ細胞ワクチン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013163134A Expired - Fee Related JP6000205B2 (ja) 2006-05-05 2013-08-06 Ｔ細胞ワクチン
JP2016003678A Withdrawn JP2016053090A (ja) 2006-05-05 2016-01-12 Ｔ細胞ワクチン

Country Status (12)

Country Link
US (1) US20100003228A1 (enExample)
EP (3) EP2420833B1 (enExample)
JP (3) JP2009536036A (enExample)
AU (1) AU2007247869B2 (enExample)
CA (1) CA2651328A1 (enExample)
DK (2) DK2016414T3 (enExample)
ES (2) ES2553192T3 (enExample)
IL (1) IL195115A (enExample)
NZ (1) NZ572644A (enExample)
PL (2) PL2016414T3 (enExample)
PT (2) PT2420833E (enExample)
WO (1) WO2007131210A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL398077A1 (pl) * 2012-02-10 2012-08-27 Krzysztof Selmaj Kompozycja farmaceutyczna oraz zastosowanie kompozycji do wytwarzania leku, do podawania naskórnego, do leczenia stwardnienia rozsianego
GB201300684D0 (en) * 2013-01-15 2013-02-27 Apitope Int Nv Peptide
US20160320408A1 (en) * 2013-12-19 2016-11-03 Opexa Therapeutics, Inc. Methods of t cell epitope profiling, making t cell compositions, and treating diseases
KR101503341B1 (ko) * 2014-03-12 2015-03-18 국립암센터 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
US20170246272A1 (en) 2014-09-05 2017-08-31 Opexa Therapeutics, Inc. Compositions and methods for treating b cell mediated autoimmune disorders
US10231033B1 (en) 2014-09-30 2019-03-12 Apple Inc. Synchronizing out-of-band content with a media stream
US10174122B2 (en) 2017-01-06 2019-01-08 Eutilex Co., Ltd. Anti-human 4-1BB antibodies and uses thereof

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5852225A (ja) * 1981-09-22 1983-03-28 Mitsui Pharmaceut Inc 脱髄疾患治療剤
US5766920A (en) * 1982-08-11 1998-06-16 Cellcor, Inc. Ex vivo activation of immune cells
US4550086A (en) * 1983-02-16 1985-10-29 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that recognize human T cells
IL69686A (en) * 1983-09-11 1988-03-31 Yeda Res & Dev Compositions containing cell membrane proteins and process for their preparation
US4608365A (en) * 1984-03-30 1986-08-26 University Of Southern California Treatment of neurologic functions
US4677061A (en) * 1984-10-19 1987-06-30 Genetic Systems Corporation T-cell lymphocyte subset monitoring of immunologic disease
US4898857A (en) * 1984-10-29 1990-02-06 Chaovanee Aroonsakul Treating control nervous system diseases
US4897389A (en) * 1984-10-29 1990-01-30 Chaovanee Aroonsakul Treating central nervous system diseases
US4902680A (en) * 1984-10-29 1990-02-20 Chaovanee Aroonsakul Treating central nervous system diseases
US4898856A (en) * 1984-10-29 1990-02-06 Chaovanee Aroonsakul Method for treating central nervous system diseases
CA1296622C (en) * 1986-08-12 1992-03-03 Jeffrey E. Anderson Method and apparatus for automated assessment of the immunoregulatory status of the mononuclear leukocyte immune system
US5849298A (en) * 1987-06-24 1998-12-15 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of bovine myelin
US5039660A (en) * 1988-03-02 1991-08-13 Endocon, Inc. Partially fused peptide pellet
US5242687A (en) * 1989-03-15 1993-09-07 Tkb Associates Limited Partnership Method of reducing cellular immune response involving T-cells using CD8-bearing antigen presenting cells
US5861164A (en) * 1989-03-21 1999-01-19 The Immune Response Corporation Vaccination against diseases resulting from pathogenic responses by specific T cell populations
US6007815A (en) * 1989-03-21 1999-12-28 The Immune Response Corporation Anti-idiotype vaccination against diseases resulting from pathogenic responses by specific T cell populations
US5837246A (en) * 1989-03-21 1998-11-17 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations
US6221352B1 (en) * 1989-03-21 2001-04-24 The Immune Response Corporation Method of preventing the proliferation of Vβ14 or Vβ17-Expressing T cells
US5612035A (en) * 1989-03-21 1997-03-18 The Immune Response Corporation Vaccination against diseases resulting from pathogenic responses by specific T cell populations
US6207645B1 (en) * 1989-03-21 2001-03-27 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations
US5614192A (en) * 1989-07-19 1997-03-25 Connective Therapeutics, Inc. T cell receptor peptides as therapeutics for immune-related disease
US5776459A (en) * 1989-07-19 1998-07-07 Connetics Corporation TCR V beta 5 peptides
US5298396A (en) * 1989-11-15 1994-03-29 National Jewish Center For Immunology And Respiratory Medicine Method for identifying T cells disease involved in autoimmune disease
WO1992001044A1 (en) * 1990-07-06 1992-01-23 Allergene, Inc. Mouse/human heterohybrid cell line el41 and methods for the production of human monoclonal antibodies
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
US6083503A (en) * 1991-08-28 2000-07-04 The United States Of America As Represented By The Department Of Health And Human Services Interleukin-2 stimulated T lymphocyte cell death for the treatment of autoimmune diseases, allergic responses, and graft rejection
US5480895A (en) * 1991-09-27 1996-01-02 New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery Method of producing antibodies to a restricted population of T lymphocytes, antibodies produced therefrom and methods of use thereof
US5545716A (en) * 1992-09-08 1996-08-13 University Of Florida Superantigen agonist and antagonist peptides
EP0688223A4 (en) * 1993-03-12 1998-05-13 Cellcor Inc -i (IN VITRO) 'ASSAY' FOR MEASURING THE DEGREE OF ACTIVATION OF IMMUNE CELLS
US5494899A (en) * 1993-04-07 1996-02-27 Oklahoma Medical Research Foundation Selective regulation of B lymphocyte precursors by hormones
IL110787A0 (en) * 1993-08-27 1994-11-11 Sandoz Ag Biodegradable polymer, its preparation and pharmaceutical composition containing it
AU693437B2 (en) * 1993-12-28 1998-07-02 Chiron Mimotopes Pty Ltd T-cell epitopes
US5552300A (en) * 1994-01-13 1996-09-03 T Cell Sciences, Inc. T cell antigen receptor V region proteins and methods of preparation thereof
US6410518B1 (en) * 1994-05-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US6033661A (en) * 1995-06-07 2000-03-07 Thomas Jefferson University Composition and method for allogenetic mononuclear cell immunotherapy
US5674487A (en) * 1994-09-28 1997-10-07 Univ Jefferson Method for treating autoimmune diseases
US5723503A (en) * 1994-09-28 1998-03-03 Thomas Jefferson University Biological treatment for rheumatoid arthritis
US6096314A (en) * 1994-10-07 2000-08-01 Yeda Research And Development Co. Ltd. Peptides and pharmaceutical compositions comprising them
FR2727117A1 (fr) * 1994-11-18 1996-05-24 Geffard Michel Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun
AU721898B2 (en) * 1994-11-18 2000-07-20 Board Of Trustees Of The Leland Stanford Junior University Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein
US6218166B1 (en) * 1994-12-09 2001-04-17 John Wayne Cancer Institute Adjuvant incorporation into antigen carrying cells: compositions and methods
US5874531A (en) * 1995-03-07 1999-02-23 President And Fellows Of Harvard College Identification of self and non-self antigens implicated autoimmune disease
US5869057A (en) * 1995-06-07 1999-02-09 Rock; Edwin P. Recombinant vaccines to break self-tolerance
SE9502921D0 (sv) * 1995-08-23 1995-08-23 Astra Ab New compounds
US5739307A (en) * 1995-08-28 1998-04-14 Washington University Polynucleotide encoding neurturin neurotrophic factor
US5716946A (en) * 1996-02-13 1998-02-10 Wisconsin Alumni Research Foundation Multiple sclerosis treatment
US5750356A (en) * 1996-05-31 1998-05-12 Anergen, Inc. Method for monitoring T cell reactivity
US5849886A (en) * 1996-07-10 1998-12-15 Oy Aboatech Ab Extraction of myelin basic protein
US20010031253A1 (en) * 1996-07-24 2001-10-18 Gruenberg Micheal L. Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
US6130087A (en) * 1996-10-07 2000-10-10 Fordham University Methods for generating cytotoxic T cells in vitro
ATE229810T1 (de) * 1996-10-11 2003-01-15 Univ California Krebs immuntherapie unter verwendung von tumorzellen kombiniert mit lymphozytmischungen
US6054292A (en) * 1997-07-18 2000-04-25 Incyte Pharmaceuticals, Inc. T-cell receptor protein
US20020009448A1 (en) * 1997-09-19 2002-01-24 Leslie P. Weiner T-cell vaccination for the treatment of multiple sclerosis
US20020072493A1 (en) * 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
US20020001841A1 (en) * 1998-06-26 2002-01-03 Keld Kaltoft Continuous t-cell lines
CA2362099C (en) * 1999-02-23 2014-05-13 Baylor College Of Medicine T cell receptor v.beta.-d.beta.-j.beta. sequence and methods for its detection
US6187750B1 (en) * 1999-08-25 2001-02-13 Everyoung Technologies, Inc. Method of hormone treatment for patients with symptoms consistent with multiple sclerosis
US6746670B2 (en) * 2000-08-15 2004-06-08 Schering Corporation Regulatory T cells; methods
KR20030062321A (ko) * 2000-08-21 2003-07-23 아피토프 테크놀러지 (브리스톨) 리미티드 펩티드 선별 방법
AU2001297741A1 (en) * 2000-11-22 2002-10-08 Diadexus, Inc. Compositions and methods relating to breast specific genes and proteins
US20030078347A1 (en) * 2001-08-28 2003-04-24 General Electric Company Triazine compounds, polymers comprising triazine structural units, and method
US7658926B2 (en) * 2001-09-14 2010-02-09 Opexa Pharmaceuticals, Inc. Autologous T-cell vaccines materials and methods
US20030153073A1 (en) * 2001-11-07 2003-08-14 Paul Rogers Expansion of T cells in vitro and expanded T cell populations
US20050181459A1 (en) * 2002-06-11 2005-08-18 Matthew Baker Method for mapping and eliminating T cell epitopes
JP2007509063A (ja) * 2003-10-17 2007-04-12 ベイラー　カレッジ　オブ　メディスン Ｃｄ８＋細胞傷害性ｔ細胞応答を増大させる方法、および多発性硬化症を処置するための方法
MXPA06004858A (es) * 2003-10-31 2007-04-16 Univ British Columbia Factores de virulencia bacteriana y sus usos.
AU2005211424A1 (en) * 2004-02-02 2005-08-18 Mixture Sciences, Inc. Peptide mixtures with immunomodulatory activity

Similar Documents

Publication Publication Date Title
Vasakova et al. Hypersensitivity pneumonitis: current concepts of pathogenesis and potential targets for treatment
Nath et al. Immunology of leprosy and diagnostic challenges
Yin et al. HLA-DM constrains epitope selection in the human CD4 T cell response to vaccinia virus by favoring the presentation of peptides with longer HLA-DM–mediated half-lives
De Groot et al. Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics
Kamala Hock immunization: a humane alternative to mouse footpad injections
ES2431891T3 (es) Antígenos de micobacterias
Dijkman et al. A protective, single-visit TB vaccination regimen by co-administration of a subunit vaccine with BCG
BR112021005702A2 (pt) método para selecionar neoepítopos
Voigt et al. Unique glandular ex-vivo Th1 and Th17 receptor motifs in Sjögren's syndrome patients using single-cell analysis
Bull et al. Immunity, safety and protection of an Adenovirus 5 prime-Modified Vaccinia virus Ankara boost subunit vaccine against Mycobacterium avium subspecies paratuberculosis infection in calves
CN116056722A (zh) Sars-cov-2疫苗
McMurry et al. Epitope-driven TB vaccine development: a streamlined approach using immuno-informatics, ELISpot assays, and HLA transgenic mice
CN101724023B (zh) 结核分枝杆菌抗原限制性表位肽
Pandey et al. Analysis of the DosR regulon genes to select cytotoxic T lymphocyte epitope specific vaccine candidates using a reverse vaccinology approach
CN113666989A (zh) 新型冠状病毒cd8+ t细胞表位肽及其用途
CN103826653A (zh) 免疫接种和诊断应用中的多瘤病毒jc肽和蛋白质
Aebischer Leishmania spp. proteome data sets: a comprehensive resource for vaccine development to target visceral leishmaniasis
DK2420833T3 (en) T-cell vaccine
EP2696891A1 (en) New vaccines for prevention and treatment of tuberculosis
Berrêdo-Pinho et al. Proteomic profile of culture filtrate from the Brazilian vaccine strain Mycobacterium bovis BCG Moreau compared to M. bovis BCG Pasteur
Lasso et al. Frequency of specific CD8+ T cells for a promiscuous epitope derived from Trypanosoma cruzi KMP‐11 protein in chagasic patients
Woolums et al. New approaches to vaccinology made possible by advances in next generation sequencing, bioinformatics and protein modeling
Miahipour et al. T Helper 1 (Th1), Th2, and Th17 responses to leishmania major lipophosphoglycan 3
Gao et al. Robust T cell responses to Pfizer/BioNTech vaccine compared to infection and evidence of attenuated peripheral CD8+ T cell responses due to COVID-19
JP2016513963A5 (enExample)